Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Highlights from the PER® CME activity "Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.

Earn CME credit by completing the full accredited activity (available through March 11, 2027):
https://www.gotoper.com/tb26-her2-trop2-nsclc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.